Embecta Corp. (NASDAQ: EMBC) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $348M. The Maz Rating grades it against the other companies in its sector.
Embecta Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.15, Embecta Corp. trades at 4.1x trailing earnings and 0.3x sales, with an EV/EBITDA of 6.1. Over the last twelve months it generated about $1.0B of revenue and $86M of net income. It runs a gross margin of 59.9%, an operating margin of 24.8% and a net margin of 8.6%. It shows return on equity of -14.0%, return on invested capital of 17.8% and a free cash flow yield of 47.3%. On the balance sheet: a debt-to-equity ratio of -2.45 and a current ratio of 1.68. Over the past 52 weeks the share price ranged from $2.77 to $14.81, with a beta of 0.81.
Embecta Corp. pays a dividend yielding 5.28%, with 31% of earnings paid out. Its Maz Dividend Score is 1.90 out of 5, ranked against the other dividend payers in its sector (Safety 2.97, Growth 1.03, Yield 4.37, Consistency 1.85).
4 Wall Street analyst ratings cover the stock: 2 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of June 2026, Embecta Corp. (EMBC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 427.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 63.1% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 427.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 63.1% / 33% · Receivables / Mkt Cap (36m) 53.6% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 427.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 63.1% / 33.33% · Receivables / Mkt Cap (24m) 53.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 124.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.6% / 33.33% · Receivables / Avg Assets (4Q) 14.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 115.0% / 33.33% · (Cash+ST Inv) / Total Assets 17.0% / 33.33% · (Cash+Recv) / Total Assets 31.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of June 2026, Embecta Corp. (EMBC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Embecta Corp. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Embecta Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated June 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.